{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:14:02Z","timestamp":1791123242324,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":988,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BiomX, Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topical antibiotics are frequently used to treat acne vulgaris. Their prolonged use, often for longer durations than recommended, has led to antibiotic resistance in Cutibacterium acnes (C. acnes), a bacterium implicated in acne pathophysiology. Bacteriophage (phage), which specifically target C. acnes by a different mechanism of action and do not harm potentially beneficial bacteria, may offer an alternative approach for improvement of the appearance of acne prone skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify and characterize C. acnes targeting phage, carry out a comprehensive preclinical safety evaluation of phages selected for further development and examine their safety, tolerability and ability to target facial C. acnes when applied topically in a cosmetic clinical study including participants with mild-to-moderate acne.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phages were isolated by conventional microbiological methods also used to examine their breadth of host range on different C. acnes strains and specificity to this bacterial species. Safety assessment of three selected phages was carried out by complete genomic analysis to assure the absence of undesired sequences and by ex vivo models employed to evaluate the safety, irritability and potential systemic bioavailability of phage applied topically. A randomized, controlled clinical study assessed safety, tolerability and efficacy in targeting facial C. acnes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Wide host range phages that also target antibiotic resistant C. acnes were identified. Their genomes were shown to be free of undesired genes. The three-phage cocktail, BX001, was not irritant to human skin or ocular tissues in ex vivo models and did not permeate through human epidermis. In a cosmetic clinical study, topically applied BX001 was safe and well tolerated and reduced the facial burden of C. acnes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Combined in silico and ex vivo approaches successfully predicted the observed safety and efficacy of C. acnes targeting phage when these were topically administered in a well-controlled cosmetic clinical study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ski2.93","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T05:42:59Z","timestamp":1643348579000},"source":"Crossref","is-referenced-by-count":35,"title":["Development of a Topical Bacteriophage Gel Targeting\n                    <i>Cutibacterium Acnes<\/i>\n                    for Acne Prone Skin and Results of a Phase 1 Cosmetic Randomized Clinical Trial"],"prefix":"10.1093","volume":"2","author":[{"given":"M.","family":"Golembo","sequence":"first","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Puttagunta","sequence":"additional","affiliation":[{"name":"BiomX Inc , Branford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5360-5543","authenticated-orcid":false,"given":"U.","family":"Rappo","sequence":"additional","affiliation":[{"name":"BiomX Inc , Branford, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Engelstein","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gahali-Sass","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moses","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kario","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ben-Dor Cohen","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nicenboim","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ben David","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sudakov","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bassan","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. B.","family":"Zak","sequence":"additional","affiliation":[{"name":"BiomX Ltd , Ness Ziona ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"2025010818063881500_ski293-bib-0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39491","article-title":"The balance of metagenomic elements shapes the skin microbiome in acne and health","volume":"6","author":"Barnard","year":"2016","journal-title":"Sci Rep"},{"key":"2025010818063881500_ski293-bib-0002","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clindermatol.2004.03.005","article-title":"Acne and propionibacterium acnes","volume":"22","author":"Bojar","year":"2004","journal-title":"Clin Dermatol"},{"key":"2025010818063881500_ski293-bib-0003","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/jid.2013.21","article-title":"Propionibacterium acnes strain populations in the human skin microbiome associated with acne","volume":"133","author":"Fitz-Gibbon","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2025010818063881500_ski293-bib-0004","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070897","article-title":"The opportunistic pathogen propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution","volume":"8","author":"McDowell","year":"2013","journal-title":"PLoS One"},{"key":"2025010818063881500_ski293-bib-0005","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: an increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025010818063881500_ski293-bib-0006","first-page":"1","article-title":"The diversity and host interactions of Propionibacterium acnes bacteriophages on human skin","author":"Liu","year":"2015","journal-title":"ISME J"},{"key":"2025010818063881500_ski293-bib-0007","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1046\/j.1365-2133.2002.04690.x","article-title":"Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study","volume":"146","author":"Coates","year":"2002","journal-title":"Br J Dermatol"},{"key":"2025010818063881500_ski293-bib-0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/dth.12391","article-title":"Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes","volume":"29","author":"Sadhasivam","year":"2016","journal-title":"Dermatol Ther"},{"key":"2025010818063881500_ski293-bib-0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2019.00513","article-title":"Advantages and limitations of bacteriophages for the treatment of bacterial infections","volume":"10","author":"Principi","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025010818063881500_ski293-bib-0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920110790725410","article-title":"Phage therapy pharmacology","volume":"11","author":"Abedon","year":"2010","journal-title":"Curr Pharm Biotechnol"},{"key":"2025010818063881500_ski293-bib-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1097(04)00041-2","article-title":"The interaction of phage and biofilms","volume":"232","author":"Sutherland","year":"2004","journal-title":"FEMS Microbiol Lett"},{"key":"2025010818063881500_ski293-bib-0012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2133.2012.10897.x","article-title":"An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case-control study","volume":"167","author":"Jahns","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025010818063881500_ski293-bib-0013","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fmb.13.47","article-title":"Phage cocktails and the future of phage therapy","volume":"8","author":"Chan","year":"2013","journal-title":"Future Microbiol"},{"key":"2025010818063881500_ski293-bib-0014","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/v11040343","article-title":"Current state of compassionate phage therapy","volume":"11","author":"McCallin","year":"2019","journal-title":"Viruses"},{"key":"2025010818063881500_ski293-bib-0015","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025010818063881500_ski293-bib-0016","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/v13071268","article-title":"The safety and toxicity of phage therapy: a review of animal and clinical studies","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"2025010818063881500_ski293-bib-0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v10040205","article-title":"Bacteriophage applications for food production and processing","volume":"10","author":"Moye","year":"2018","journal-title":"Viruses"},{"key":"2025010818063881500_ski293-bib-0018","first-page":"1","volume-title":"Bacteriophage therapy: scientific and regulatory issues public workshop","year":"2017"},{"key":"2025010818063881500_ski293-bib-0019","doi-asserted-by":"crossref","first-page":"e00279","DOI":"10.1128\/mBio.00279-12","article-title":"Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates","volume":"3","author":"Marinelli","year":"2012","journal-title":"mBio"},{"key":"2025010818063881500_ski293-bib-0020","volume-title":"FDA bacteriological analytical manual appendix 2: Most probable number from serial dilutions","author":"Blodgett","year":"2020"},{"key":"2025010818063881500_ski293-bib-0021","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/j.1551-8833.1942.tb19721.x","article-title":"Bacterial densities from fermentation tube tests","volume":"34","author":"Thomas","year":"1942","journal-title":"J Am Water Work Assoc"},{"key":"2025010818063881500_ski293-bib-0022","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S002217240001192X","article-title":"Sampling errors in the determination of bacterial or virus density by the dilution method","volume":"39","author":"Haldane","year":"1939","journal-title":"J Hyg (Lond)"},{"key":"2025010818063881500_ski293-bib-0023","volume-title":"Introduced Genetic Material","year":"2020"},{"key":"2025010818063881500_ski293-bib-0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/nar\/gkl791","article-title":"MvirDB \u2013 a microbial database of protein toxins, virulence factors and antibiotic resistance genes for bio-defence applications","volume":"35","author":"Zhou","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"2025010818063881500_ski293-bib-0025","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1128\/AAC.00419-13","article-title":"The comprehensive antibiotic resistance database","volume":"57","author":"McArthur","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010818063881500_ski293-bib-0026","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J Mol Biol"},{"key":"2025010818063881500_ski293-bib-0027","doi-asserted-by":"publisher","DOI":"10.1787\/9789264242548-en","volume-title":"Test No. 492: reconstructed human Cornea-like Epithelium (RhCE) test method for identifying chemicals not requiring classification and labelling for eye irritation or serious eye damage","author":"OECD","year":"2019"},{"key":"2025010818063881500_ski293-bib-0028","doi-asserted-by":"publisher","DOI":"10.1787\/9789264242845-en","volume-title":"Test No. 439: in vitro skin irritation: reconstructed human epidermis test method","author":"OECD","year":"2021"},{"key":"2025010818063881500_ski293-bib-0029","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010818063881500_ski293-bib-0030","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"2025010818063881500_ski293-bib-0031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","article-title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection","volume":"5","author":"Petrovic Fabijan","year":"2020","journal-title":"Nat Microbiol"},{"key":"2025010818063881500_ski293-bib-0032","first-page":"1","article-title":"Safety and efficacy of phage therapy via the intravenous route","volume":"363","author":"Speck","year":"2015","journal-title":"FEMS Microbiol Lett"},{"key":"2025010818063881500_ski293-bib-0033","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nmeth.f.303","article-title":"QIIME allows analysis of high-throughput community sequencing data","volume":"7","author":"Caporaso","year":"2010","journal-title":"Nat Methods"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ski2.93","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ski2.93","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/2\/ski2.93\/59726639\/skinhd_2_2_e93.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/2\/2\/ski2.93\/59726639\/skinhd_2_2_e93.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T13:06:57Z","timestamp":1736341617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.93\/7750825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.93","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,1,28]]},"article-number":"ski2.93"}}